The Centers for Disease Control and Prevention’s (CDC) recent decision to award Pfizer $1.24 billion for COVID-19 vaccines has renewed debate over the government’s continued investment in mRNA technology.
The contracts, awarded on June 1, include about $735.7 million for pediatric COVID-19 vaccines and nearly $505.3 million for adult doses for fiscal year 2026-2027.
Critics say the funding reflects a continued commitment to vaccines associated with high rates of serious injuries and deaths, and a lack of adequate safety testing and monitoring.
Public health experts argue the investment is necessary to protect vulnerable populations and prepare for future outbreaks.
The latest contracts come as mRNA technology expands beyond COVID-19.
A recent review in Human Vaccines & Immunotherapeutics found that mRNA-based therapeutics were identified in more than 550 registered clinical trials. The authors reported that more than 90% of the projects involved mRNA vaccines and that most products remain in early-stage testing before broader adoption.
‘Unnecessary and often harmful injections’
The procurement of monetary resources signals that federal officials intend to continue investing heavily in mRNA technology despite declining public demand and ongoing controversy over vaccine safety monitoring, critics say.
Jeffrey Tucker, president and founder of the Brownstone Institute, told The Defender there was “no scientific justification” or “market demand” for the latest mRNA vaccine funding.
“This raises a serious question concerning how these captured agencies really work,” Tucker said. “We are talking about vast amounts of tax dollars flowing to support unnecessary and often harmful injections.”
Hellbound and Down 